

Special Issue

Vaccines and Passive Immune Strategies in Veterinary Medicine

Message from the Guest Editors

The aim of the issue will be to summarize the results and performances of the latest vaccines and passive immune therapies that are under development for animal diseases. We also invite data regarding the performance, stability and efficacy of products that have already been launched on the veterinary market. We also encourage authors to submit for publication their results from research teams working in the development of animals' models for vaccine potency testing. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following topics:

- Targeted subunit and VLP veterinary vaccines;
- mRNA and DNA vaccines for veterinary use;
- IgY therapies for animal diseases;
- Llama-derived nanobodies against animal diseases;
- Equine Fab antiserum to prevent and treat animal diseases.

Guest Editors

Dr. Viviana Parreno

1. INCUINTA, Instituto de Virología e Innovaciones Tecnológicas (IVIT), Instituto Nacional de Tecnología Agro-Pecuaria (INTA)-CONICET, Ciudad Autónoma de Buenos Aires C1033AAE, Argentina
2. Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24060, USA
3. Instituto de Biotecnología, Unahur, Universidad Nacional de Hurlingham, Buenos Aires, Argentina

Dr. Marina Bok

INCUINTA, Instituto de Virología e Innovaciones Tecnológicas (IVIT), Instituto Nacional de Tecnología Agro-Pecuaria (INTA)-CONICET, Ciudad Autónoma de Buenos Aires C1033AAE, Argentina

Deadline for manuscript submissions

closed (30 November 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/175324

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).